Browse the evidence

Discontinuation of incretin-based therapies (GLP-1/GIP agonists) consistently leads to rapid and clinically meaningful weight regain, typically recovering two-thirds of lost weight within one year, alongside the reversal of cardiometabolic improvements.

If you stop taking incretin-based weight loss medication, you will likely regain about two-thirds of the weight you lost within a year. This is not a failure of willpower but a biological response to the loss of the drug's hormonal effects. To maintain your weight loss, you likely need to continue the medication long-term or use very aggressive, sustained lifestyle interventions, though even those are often insufficient to prevent significant regain.

GLP-1 and dual GLP-1/GIP receptor agonists (semaglutide, tirzepatide, liraglutide) produce significant, clinically meaningful weight loss (10-21%) and reduce the incidence of type 2 diabetes in adults with overweight or obesity, with effects rivaling metabolic surgery.

GLP-1 and dual agonists are highly effective for significant weight loss (up to 21%) and diabetes prevention in adults with obesity. They work by targeting hormonal pathways to reduce appetite and improve insulin sensitivity. While effective, they require long-term use to maintain benefits, as stopping leads to significant weight regain. Side effects like nausea and diarrhea are common but manageable, and the choice of agent depends on individual tolerance and specific health goals.

mTORC1 is the central integrator of anabolic signals from both resistance exercise and dietary protein, mediating muscle protein synthesis and hypertrophy.

Understanding mTORC1 is important for researchers but has limited direct practical application for the average person. Focus on the external drivers: lift weights and eat enough protein.

Metformin reduces the risk of progression from prediabetes to type 2 diabetes by 31% and is recommended for specific high-risk subgroups (age 25-59, BMI ≥35, FPG ≥6.1 mmol/L, or history of gestational diabetes).

If lifestyle changes alone are not enough, your doctor may prescribe metformin. It is typically started at a low dose (500 mg) and increased to 1,500 mg daily to minimize stomach issues. Use the extended-release version if possible. Monitor your blood sugar every 6 months. This is particularly recommended if you are younger, have a higher BMI, or have a history of gestational diabetes.

Second-generation obesity management medications (semaglutide and tirzepatide) produce 15-20% body weight loss, significantly exceeding the 5-10% typically achieved by lifestyle interventions alone.

Second-generation obesity medications like semaglutide and tirzepatide are significantly more effective for weight loss than lifestyle changes alone, achieving 15-20% body weight reduction. They work by targeting hormonal pathways that regulate appetite and metabolism, addressing the biological drivers of obesity rather than relying solely on willpower.

Discontinuation of second-generation OMMs leads to significant weight regain, highlighting the chronic nature of obesity and the need for long-term management or intensive lifestyle support upon discontinuation.

Stopping OMMs typically leads to significant weight regain. If you choose to discontinue, work with your healthcare provider to intensify lifestyle interventions, including dietary strategies and physical activity, to help maintain your weight loss.

Combining basal insulin with a GLP-1 receptor agonist (GLP-1RA) significantly reduces HbA1c, body weight, and hypoglycemia risk compared to basal insulin alone or intensified insulin regimens.

If you are on basal insulin and your blood sugar is still high, ask your doctor about adding a GLP-1 receptor agonist (like liraglutide or dulaglutide). This combination lowers blood sugar more effectively than increasing insulin alone, helps you lose weight, and reduces the risk of low blood sugar episodes.

Once-weekly subcutaneous semaglutide 2.4 mg produces significant weight loss in adults with overweight or obesity regardless of baseline characteristics such as age, race, or baseline BMI, although females and those with lower baseline body weight experience greater magnitude of loss.

Semaglutide 2.4mg weekly, combined with lifestyle changes, is effective for weight loss across diverse demographics. While women and those starting at a lower weight may lose more, men and those with higher starting weights still achieve significant, clinically meaningful weight reduction. Do not skip treatment based on demographics.

Once-weekly subcutaneous semaglutide 2.4 mg combined with lifestyle intervention induces significant weight loss and improves cardiometabolic risk factors in adults with overweight/obesity and type 2 diabetes.

If you have type 2 diabetes and are overweight, adding once-weekly semaglutide 2.4 mg to your diet and exercise routine can lead to significantly more weight loss (about 10% of body weight on average) and better blood sugar control than diet and exercise alone. While you may experience temporary stomach issues, the long-term health benefits are substantial.

Once-weekly subcutaneous semaglutide 2.4 mg combined with lifestyle intervention induces a mean body weight loss of approximately 15% (14.9%) over 68 weeks in adults with overweight or obesity, significantly outperforming placebo.

If you have a BMI of 30 or higher (or 27 or higher with a weight-related health issue), adding once-weekly semaglutide 2.4 mg to your lifestyle changes can help you lose about 15% of your body weight over 16 months. This is significantly more than lifestyle changes alone. Be prepared for possible mild, temporary stomach issues, but the weight loss benefits are substantial and come with improvements in blood pressure and blood sugar.

Once-weekly subcutaneous semaglutide 2.4 mg produces significant weight loss in adults with overweight or obesity, with efficacy largely independent of baseline characteristics such as age, race, BMI, and glycemic status, though females and those with lower baseline body weight experience greater magnitude of loss.

If you have obesity or overweight, once-weekly semaglutide (2.4 mg) is a highly effective treatment for weight loss, regardless of your age, race, or starting weight. However, be aware that women and those with a lower starting body weight tend to lose more weight than men or those with a higher starting body weight. This treatment is used alongside lifestyle changes.

Tirzepatide (5-15 mg weekly) produces superior weight loss (10.7-20.9%) compared to placebo in adults with obesity (BMI ≥30 or ≥27 with comorbidities) via dual GIP/GLP-1 receptor agonism.

Tirzepatide is a once-weekly injection that significantly reduces body weight (up to 20%+) in obese adults. It works by mimicking gut hormones to suppress appetite and slow digestion. Start with the lowest dose and increase gradually to minimize stomach upset. Combine with a 500-calorie daily deficit and 150 minutes of weekly exercise for best results.

Once-weekly subcutaneous semaglutide (up to 2.4 mg) significantly reduces body weight, BMI, and waist circumference in adults with obesity or overweight compared to placebo, with effects demonstrating a dose-response relationship.

For adults with obesity or overweight, once-weekly semaglutide (titrated up to 2.4 mg) combined with lifestyle changes is a highly effective medical intervention for significant weight loss, outperforming lifestyle changes alone. While gastrointestinal side effects like nausea are common, they are usually manageable and do not typically lead to stopping treatment.

Once-weekly semaglutide improves cardiometabolic markers including HbA1c, fasting plasma glucose, blood pressure, and lipid profiles in overweight/obese patients, independent of or alongside weight loss.

Beyond weight loss, semaglutide helps improve blood sugar control (HbA1c), blood pressure, and lipid profiles in overweight/obese individuals, offering broader cardiovascular protection.

GLP-1 receptor agonists treat type-2 diabetes and obesity by mimicking the endogenous hormone GLP-1, which stimulates glucose-dependent insulin secretion, slows gastric emptying, and inhibits food intake.

GLP-1 receptor agonists are effective, FDA-approved treatments for type-2 diabetes and obesity. They work by mimicking a natural gut hormone to increase insulin, slow digestion, and reduce appetite. Consult a doctor to see if a GLP-1 based medication is appropriate for your health profile.

Long-acting GLP-1 receptor agonists (liraglutide and semaglutide) improve glycemic control and promote significant weight loss in individuals with type 2 diabetes and obesity by binding to GLP-1 receptors in the pancreas and brain.

GLP-1 agonists like liraglutide and semaglutide are effective treatments for type 2 diabetes and obesity. They work by mimicking a natural hormone to regulate blood sugar and reduce appetite. Liraglutide is approved at 3.0 mg daily for obesity, while semaglutide is being developed for similar uses and oral administration. These drugs target receptors in the pancreas and brain to achieve their effects.

Higher levels of physical activity reduce the risk of six specific cancer sites (bladder, breast, colon, endometrial, esophageal adenocarcinoma, gastric cardia) with strong evidence, while moderate evidence supports inverse associations with lung, ovarian, pancreatic, and renal cancers.

Aim for regular physical activity to lower cancer risk. You do not need a specific dose to start; even breaking up long periods of sitting with standing or walking offers benefits. Consistency matters more than intensity for general risk reduction.

Prescription omega-3s (4 g/d EPA-only) reduce major adverse cardiovascular events by 25% in high-risk patients with hypertriglyceridemia who are already taking statins.

If you are at high risk for heart disease and have high triglycerides, ask your doctor about adding prescription EPA-only omega-3s (like Vascepa) to your statin. The REDUCE-IT trial showed this combination reduced major heart events by 25% compared to placebo.

GLP-1 receptor agonists (e.g., exenatide, liraglutide, semaglutide) effectively treat type 2 diabetes and obesity by stimulating glucose-dependent insulin secretion, inhibiting glucagon secretion, slowing gastric emptying, and reducing appetite.

GLP-1 receptor agonists are a highly effective, FDA-approved class of medications for treating type 2 diabetes and obesity. They work by mimicking a natural gut hormone to increase insulin when blood sugar is high, decrease glucagon, slow digestion, and reduce appetite. While they can cause initial nausea, this is often manageable with slow dose increases. They offer the added benefit of cardiovascular protection for many patients.

Oral semaglutide at 7 mg/d and 14 mg/d, when added to metformin with or without sulfonylurea, significantly reduces glycated hemoglobin (HbA1c) and body weight compared to sitagliptin in adults with type 2 diabetes.

If you have type 2 diabetes that isn't well-controlled with metformin (with or without sulfonylurea), adding oral semaglutide at 7 mg or 14 mg daily can significantly lower your HbA1c and help you lose weight compared to taking sitagliptin. Start with 3 mg, then increase to 7 mg after 4 weeks, and finally to 14 mg after another 4 weeks. Take it first thing in the morning with water, at least 30 minutes before eating or taking other medications. The 3 mg dose alone is not effective for lowering HbA1c compared to sitagliptin, so sticking to the higher doses is important.

High-dose purified eicosapentaenoic acid (EPA) reduces major adverse cardiovascular events by 25% in high-risk patients with elevated triglycerides, an effect not observed with EPA/DHA combinations.

If you have high triglycerides and heart disease risk, ask your doctor about prescription EPA (icosapent ethyl). It has been proven to reduce heart attacks and strokes in people already taking statins, whereas standard fish oil supplements containing DHA have not shown the same benefit.

GLP-1 receptor agonists (GLP-1RA) provide superior glycemic control and weight loss compared to DPP-4 inhibitors in patients with type 2 diabetes, despite a higher incidence of gastrointestinal side effects.

If you have Type 2 Diabetes and are struggling with blood sugar and weight despite taking metformin, switching from a DPP-4 inhibitor (like sitagliptin) to a GLP-1 receptor agonist (like semaglutide or liraglutide) is likely to give you better blood sugar control and more weight loss. Be prepared for some initial stomach upset (nausea), which usually gets better over time. If you strongly dislike injections, ask about oral semaglutide, which offers similar benefits without needles.

Semaglutide 2.4 mg administered subcutaneously once weekly, used as an adjunct to lifestyle interventions, produces clinically significant weight loss in adults with obesity or overweight, with efficacy superior to the previously approved GLP-1 receptor agonist liraglutide.

If you have obesity or overweight and have struggled to lose weight with diet and exercise alone, adding semaglutide 2.4 mg (a once-weekly injection) to your lifestyle changes can lead to significantly greater weight loss than lifestyle changes alone. This medication works by mimicking a hormone that reduces hunger and increases fullness. It is most effective when combined with a modest calorie deficit and regular physical activity. Previous medications may not be as effective, and this treatment offers a more durable solution for weight management, including maintenance over time.

Testosterone treatment in older men with unequivocally low testosterone levels significantly improves sexual activity, libido, and erectile function.

If you are an older man with confirmed low testosterone and sexual concerns, testosterone therapy can significantly improve your sexual activity, desire, and erectile function. The treatment involves daily application of a gel, with dose adjustments to keep levels in the normal range for young men. While long-term safety requires more data, this study found no increase in prostate or heart issues over one year.